Skip to main content
Top
Published in: Clinical Rheumatology 5/2009

01-05-2009 | Brief Report

Prolonged synovitis in pediatric Lyme arthritis cannot be predicted by clinical or laboratory parameters

Authors: AnneMarie C. Brescia, Carlos D. Rose, Paul T. Fawcett

Published in: Clinical Rheumatology | Issue 5/2009

Login to get access

Abstract

Ten percent of Lyme arthritis (LA) patients have continued synovitis despite antimicrobial therapy. The current study was designed to (1) investigate predictors of prolonged disease and (2) further define natural history of pediatric LA. Medical records of 94 children fulfilling Centers for Disease Control criteria for Lyme disease were reviewed, classified into groups according to duration of synovitis, and SPSS statistical software was used for analysis. Thirty-nine percent required >6 months and 13% required >12 months to resolve LA. Pearson correlation between duration of symptoms of LA pretreatment and duration of synovitis was not significant. When patients were stratified by group, no differences were found for age, antinuclear antibodies positivity, enzyme-linked immunosorbent assay titer, or reactivity of Western blot using parametric and nonparametric tests. Linear and logistic regression showed no predictors of disease duration. One third of pediatric LA patients require >6 months to resolve synovitis. Duration is not associated with delay in treatment, age, or seroreactivity.
Literature
1.
2.
go back to reference Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH 3rd, Liu NY, Schmid CH (1994) Treatment of Lyme arthritis. Arthritis Rheum 37(6):878–888PubMedCrossRef Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH 3rd, Liu NY, Schmid CH (1994) Treatment of Lyme arthritis. Arthritis Rheum 37(6):878–888PubMedCrossRef
3.
go back to reference Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54(10):3079–3086PubMedCrossRef Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54(10):3079–3086PubMedCrossRef
4.
go back to reference Steere AC, Duray PH, Butcher EC (1988) Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 31(4):487–495PubMedCrossRef Steere AC, Duray PH, Butcher EC (1988) Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 31(4):487–495PubMedCrossRef
5.
go back to reference Fawcett P, Fawcett L, Vinette K, Stetson T, Rose C (2003) Proliferation of synoviocytes in antibiotic resistant Lyme arthritis. Arthritis Rheum 48(9):S519 Fawcett P, Fawcett L, Vinette K, Stetson T, Rose C (2003) Proliferation of synoviocytes in antibiotic resistant Lyme arthritis. Arthritis Rheum 48(9):S519
6.
go back to reference Eberhard BA, Laxer RM, Andersson U, Silverman ED (1994) Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 96(2):260–266PubMedCrossRef Eberhard BA, Laxer RM, Andersson U, Silverman ED (1994) Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 96(2):260–266PubMedCrossRef
Metadata
Title
Prolonged synovitis in pediatric Lyme arthritis cannot be predicted by clinical or laboratory parameters
Authors
AnneMarie C. Brescia
Carlos D. Rose
Paul T. Fawcett
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1100-8

Other articles of this Issue 5/2009

Clinical Rheumatology 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine